In a recent late-stage trial, Eli Lilly’s weight loss drug Zepbound has shown promising benefits for patients with heart failure and obesity. This adds to the growing body of evidence that GLP-1 drugs like Zepbound may have broader health benefits beyond weight loss and blood sugar regulation. The results of the phase three trial are set to be submitted to regulators in the U.S. and other agencies, potentially leading to wider insurance coverage for these treatments.
Patients who took Zepbound were found to be 38% less likely to be hospitalized or die from heart complications compared to those who received a placebo. Additionally, they were less likely to need to increase their heart failure medication. Zepbound also significantly improved heart failure symptoms and physical limitations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, as well as some with diabetes.
HFpEF is a condition where the heart is unable to pump enough blood to meet the body’s needs, resulting in symptoms such as fatigue, shortness of breath, and reduced ability to exercise. In the U.S., approximately 6.7 million adults aged 20 and above have heart failure, with HFpEF accounting for nearly half of all cases. Around 60% of HFpEF patients in the U.S. also have obesity, highlighting the need for effective treatment options.
The safety data on Zepbound was consistent with previous trials, with the most common side effects being gastrointestinal issues like nausea and diarrhea. These side effects were generally mild to moderate in severity. Eli Lilly plans to present the data at a medical meeting and submit it to a peer-reviewed journal for further validation.
Eli Lilly’s main rival in the GLP-1 market, Novo Nordisk, has also made strides in the treatment of patients with HFpEF. Novo Nordisk’s weight loss drug Wegovy has been approved by the FDA for reducing the risk of serious heart complications in patients. Both companies are also exploring the use of their drugs in patients with chronic kidney disease and fatty liver disease, among other conditions.
GLP-1 drugs like Zepbound and Wegovy work by mimicking hormones in the gut to suppress appetite and regulate blood sugar. However, Zepbound targets both the GLP-1 and GIP hormone receptors, while Wegovy targets only the GLP-1 receptor. This dual-target approach may provide additional benefits for patients with heart failure and obesity.
Overall, the results of the trial highlight the potential of Eli Lilly’s weight loss drug Zepbound in improving outcomes for patients with heart failure and obesity. The data presented adds to the growing body of evidence supporting the use of GLP-1 drugs in a variety of health conditions. Further research and regulatory approvals may expand the availability of these treatments for patients in need.